SciSparc Doses First Patient in Autism Trial
Ticker: SPRC · Form: 6-K · Filed: Mar 15, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, drug-development, autism, press-release
TL;DR
SciSparc dosed first patient in ASD trial, potentially big news for autism treatment.
AI Summary
On March 14, 2024, SciSparc Ltd. announced a significant milestone by dosing the first patient in its Phase II clinical trial for Autism Spectrum Disorder (ASD). This trial is investigating the safety and efficacy of SCI-110, a combination of palmitoylethanolamide (PEA) and SciSparc's proprietary Cannabidiol (CBD) formulation, in treating symptoms associated with ASD.
Why It Matters
This marks a critical step in developing a potential new treatment for Autism Spectrum Disorder, a condition with significant unmet medical needs.
Risk Assessment
Risk Level: medium — Clinical trials are inherently risky, with outcomes uncertain and subject to regulatory approval.
Key Players & Entities
- SciSparc Ltd. (company) — The company filing the report and conducting the trial.
- SCI-110 (drug_candidate) — The drug candidate being tested in the clinical trial.
- Autism Spectrum Disorder (condition) — The condition being targeted by the clinical trial.
- March 14, 2024 (date) — The date the press release was issued.
FAQ
What is the specific drug candidate being tested in the Phase II clinical trial for Autism Spectrum Disorder?
The drug candidate being tested is SCI-110, a combination of palmitoylethanolamide (PEA) and SciSparc's proprietary Cannabidiol (CBD) formulation.
When did SciSparc Ltd. announce the dosing of the first patient?
SciSparc Ltd. announced the dosing of the first patient on March 14, 2024.
What is the primary goal of the Phase II clinical trial mentioned in the filing?
The primary goal of the Phase II clinical trial is to investigate the safety and efficacy of SCI-110 in treating symptoms associated with Autism Spectrum Disorder (ASD).
What is the address of SciSparc Ltd.'s principal executive offices?
The address of SciSparc Ltd.'s principal executive offices is 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.
Does SciSparc Ltd. file annual reports under Form 20-F or Form 40-F?
SciSparc Ltd. files annual reports under Form 20-F.
Filing Stats: 330 words · 1 min read · ~1 pages · Grade level 8.8 · Accepted 2024-03-15 08:00:02
Filing Documents
- ea0201843-6k_scisparc.htm (6-K) — 19KB
- ea020184301ex99-1_scisparc.htm (EX-99.1) — 10KB
- 0001213900-24-022825.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: March 15, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3